# Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age

> **NCT05301322** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1471 (actual)

## Conditions studied

- Respiratory Syncytial Virus

## Interventions

- **BIOLOGICAL:** RSVpreF Vaccine
- **OTHER:** Placebo
- **BIOLOGICAL:** Seasonal Inactivated Influenza Vaccine

## Key facts

- **NCT ID:** NCT05301322
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-13
- **Primary completion:** 2022-10-12
- **Final completion:** 2022-10-12
- **Target enrollment:** 1471 (ACTUAL)
- **Last updated:** 2023-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05301322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05301322, "Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT05301322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*